StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Actinium Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$22.66M. For fiscal 2025 it was -$24.58M. The highest annual figure on record is $8.64M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.58M–
FY2024Dec 31, 2024-$33.07M–
FY2023Dec 31, 2023-$47.34M-647.6%
FY2022Dec 31, 2022$8.64M–
FY2021Dec 31, 2021-$20.87M–
FY2020Dec 31, 2020-$21.62M–
FY2019Dec 31, 2019-$21.46M–
FY2018Dec 31, 2018-$20.57M–
FY2017Dec 31, 2017-$21.55M–
FY2016Dec 31, 2016-$20.79M–
FY2015Dec 31, 2015-$18.54M–
FY2014Dec 31, 2014-$14.35M–
FY2013Dec 31, 2013-$6.29M–
FY2012Dec 31, 2012-$5.21M–
FY2011Dec 31, 2011-$517.59K-6706.2%
FY2010Dec 31, 2010$7.84K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.18M–
Q1 FY2026Mar 31, 2026-$5.87M–
Q4 FY2025Dec 31, 2025-$5.29M–
Q3 FY2025Sep 30, 2025-$6.33M–
Q2 FY2025Jun 30, 2025-$5.39M–
Q1 FY2025Mar 31, 2025-$7.57M–
Q4 FY2024Dec 31, 2024-$5.75M–
Q3 FY2024Sep 30, 2024-$11.98M–
Q2 FY2024Jun 30, 2024-$7.97M–
Q1 FY2024Mar 31, 2024-$7.37M–
Q4 FY2023Dec 31, 2023-$7.49M–
Q3 FY2023Sep 30, 2023-$11.13M–
Q2 FY2023Jun 30, 2023-$13.64M-148.9%
Q1 FY2023Mar 31, 2023-$15.08M–
Q4 FY2022Dec 31, 2022-$7.78M–
Q3 FY2022Sep 30, 2022-$5.72M–
Q2 FY2022Jun 30, 2022$27.92M–
Q1 FY2022Mar 31, 2022-$5.78M–
Q4 FY2021Dec 31, 2021-$5.05M–
Q3 FY2021Sep 30, 2021-$5.59M–
Q2 FY2021Jun 30, 2021-$4.58M–
Q1 FY2021Mar 31, 2021-$5.64M–
Q4 FY2020Dec 31, 2020-$6.26M–
Q3 FY2020Sep 30, 2020-$4.99M–
Q2 FY2020Jun 30, 2020-$4.51M–
Q1 FY2020Mar 31, 2020-$5.85M–
Q4 FY2019Dec 31, 2019-$5.01M–
Q3 FY2019Sep 30, 2019-$5.60M–
Q2 FY2019Jun 30, 2019-$5.36M–
Q1 FY2019Mar 31, 2019-$5.49M–
Q4 FY2018Dec 31, 2018-$4.29M–
Q3 FY2018Sep 30, 2018-$6.61M–
Q2 FY2018Jun 30, 2018-$4.21M–
Q1 FY2018Mar 31, 2018-$5.46M–
Q4 FY2017Dec 31, 2017-$3.17M–
Q3 FY2017Sep 30, 2017-$5.87M–
Q2 FY2017Jun 30, 2017-$7.14M–
Q1 FY2017Mar 31, 2017-$5.37M–
Q4 FY2016Dec 31, 2016-$4.24M–
Q3 FY2016Sep 30, 2016-$5.57M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?